WuXi XDC Cayman (HKG:2268) said it will raise the annual cap under its existing antibodies master services agreement with WuXi Biologics (HKG:2269) to 3 billion yuan for 2025, up from 2 billion yuan, according to a Tuesday Hong Kong bourse filing.

It said rapid growth in its ADC CRDMO operations is expected to push transaction amounts past the initial limit.

WuXi XDC also signed a new three-year antibodies master services agreement with WuXi Biologics, effective Jan. 1, 2026, subject to independent shareholder approval.

The proposed annual caps are set at 3 billion yuan for 2026 and 4 billion yuan for both 2027 and 2028.

Other changes include a 170 million yuan cap on project-management services for 2025, with proposed 200 million yuan limits in 2026-27, along with revised caps for raw-materials and general-services agreements through 2028.

New agreements for inventory sharing and conjugation discovery carry smaller caps of 20 million-70 million yuan across 2025-27.

WuXi XDC said the revisions and renewals are intended to secure supply and services as demand rises and capacity expands at its Wuxi and Singapore sites.